Septerna Inc (SEPN) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

33/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

69

Gaining

Sentiment

61

Bullish

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Jeffrey T. Finer
Listed since: Oct 25, 2024
Employees: 123

Market position

Day range

Current $40.00

$39.96$41.415

52-week range

Current $40.00

$11.70$51.10

Open: $41.415
Previous close: $40.79
Volume: 289.81K; 0.69× average
Average volume: 417.39K; Average daily volume
Market cap: 1.8B USD
Beta: 2.28; Market reference 1
50-day average: $36.847; +8.56% above average
200-day average: $28.7435; +39.16% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -74.07×
P/B (TTM): 4.66×
P/S (TTM): 18.23×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 99.57%
Operating margin: -44.04%
Net margin: -24.51%

Financial health

Debt / equity: 0.06×
Altman Z-score: 6.15
Piotroski F-score: 3 of 9

Earnings

EPS beat rate: 38%; 3 beats, 5 misses, 0 met estimates
Average EPS surprise: -251.35%; 8 comparable reports
Latest EPS result: -0.29; Estimate -0.43 · Beat by 31.92%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$52.00

30.00% upside

Past 12 months12-month forecastHigh $60.00Average $52.00Low $43.00

Rating distribution

9 ratings

Strong buy111%

Buy889%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

9 institutions

Jones TradingmaintainBuyAug 13, 2026

Raymond JamesmaintainStrong BuyJun 8, 2026

HC Wainwright& Co.maintainBuyMar 2, 2026

SEPN news

zacks.comAug 10, 2026

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.56 per share a year ago.

Read source

fool.comJul 5, 2026

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale.

Read source

fool.comJun 29, 2026

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing…

Read source

businesswire.comJun 8, 2026

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first…

Read source